12/4
02:02 pm
rna
Avidity Biosciences, Inc. (RNA): A Bull Case Theory [Yahoo! Finance]
Low
Report
Avidity Biosciences, Inc. (RNA): A Bull Case Theory [Yahoo! Finance]
11/21
05:30 pm
rna
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX
11/20
05:22 am
rna
Novartis sees sales boost from key cancer drugs [Yahoo! Finance Canada]
Low
Report
Novartis sees sales boost from key cancer drugs [Yahoo! Finance Canada]
11/20
05:13 am
rna
Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs [CNBC]
Low
Report
Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs [CNBC]
11/19
09:13 am
rna
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
Low
Report
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
11/12
08:05 am
rna
Avidity Biosciences (NASDAQ:RNA) had its "hold" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Avidity Biosciences (NASDAQ:RNA) had its "hold" rating reaffirmed by analysts at Cowen Inc.
11/11
08:08 am
rna
Avidity Biosciences (NASDAQ:RNA) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $72.00 price target on the stock.
Low
Report
Avidity Biosciences (NASDAQ:RNA) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $72.00 price target on the stock.
11/10
04:58 pm
rna
Avidity Biosciences GAAP EPS of -$1.27 misses by $0.16, revenue of $12.48M [Seeking Alpha]
Low
Report
Avidity Biosciences GAAP EPS of -$1.27 misses by $0.16, revenue of $12.48M [Seeking Alpha]
11/10
04:32 pm
rna
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights [Yahoo! Finance]
Low
Report
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights [Yahoo! Finance]
11/10
04:05 pm
rna
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Low
Report
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
11/7
04:34 pm
rna
Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights
Neutral
Report
Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights
11/4
10:18 am
rna
Purpose In The Pressure: Catherine Dargan On Building Billion-Dollar Deals [Forbes]
Low
Report
Purpose In The Pressure: Catherine Dargan On Building Billion-Dollar Deals [Forbes]
10/31
08:08 pm
rna
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) [Yahoo! Finance]
Low
Report
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) [Yahoo! Finance]
10/30
10:48 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Wolfe Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Wolfe Research from a "strong-buy" rating to a "hold" rating.
10/29
09:04 am
rna
Avidity Biosciences (NASDAQ:RNA) had its "hold" rating reaffirmed by analysts at TD Cowen. They now have a $74.00 price target on the stock, down previously from $78.00.
Low
Report
Avidity Biosciences (NASDAQ:RNA) had its "hold" rating reaffirmed by analysts at TD Cowen. They now have a $74.00 price target on the stock, down previously from $78.00.
10/29
08:02 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
10/29
08:02 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Chardan Capital from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Chardan Capital from a "strong-buy" rating to a "hold" rating.
10/29
06:02 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Cowen Inc from a "buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Cowen Inc from a "buy" rating to a "hold" rating.
10/28
02:42 pm
rna
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
Low
Report
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
10/28
01:55 pm
rna
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders
Low
Report
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders
10/28
06:40 am
rna
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
Low
Report
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
10/28
06:19 am
rna
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
10/28
06:01 am
rna
Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Royal Bank Of Canada.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Royal Bank Of Canada.
10/28
06:01 am
rna
Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Loop Capital.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Loop Capital.
10/28
06:01 am
rna
Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Chardan Capital.
Low
Report
Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Chardan Capital.